ES2901769T3 - Uso de variantes de péptidos natriuréticos tipo c para tratar la osteoartritis - Google Patents
Uso de variantes de péptidos natriuréticos tipo c para tratar la osteoartritis Download PDFInfo
- Publication number
- ES2901769T3 ES2901769T3 ES16852866T ES16852866T ES2901769T3 ES 2901769 T3 ES2901769 T3 ES 2901769T3 ES 16852866 T ES16852866 T ES 16852866T ES 16852866 T ES16852866 T ES 16852866T ES 2901769 T3 ES2901769 T3 ES 2901769T3
- Authority
- ES
- Spain
- Prior art keywords
- cnp
- seq
- osteoarthritis
- cartilage
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2901769T3 true ES2901769T3 (es) | 2022-03-23 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16852866T Active ES2901769T3 (es) | 2015-12-08 | 2016-12-08 | Uso de variantes de péptidos natriuréticos tipo c para tratar la osteoartritis |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4019038A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7104625B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180088459A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697766A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016365751B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007315A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3386531T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2901769T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20211908T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE057083T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL259690B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018006986A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3386531T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3386531T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2759679C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017100400A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389511B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| IL318754A (en) | 2016-01-08 | 2025-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| JP6968802B2 (ja) | 2016-01-08 | 2021-11-17 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 環部分にキャリア結合を有するｃｎｐプロドラッグ |
| MY195190A (en) | 2016-01-08 | 2023-01-11 | Ascendis Pharma Growth Disorders As | Controlled-Release Cnp Agonists With Increased Nep Stability |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| LT3518930T (lt) | 2016-09-29 | 2023-05-10 | Ascendis Pharma Growth Disorders A/S | Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais |
| US20210228497A1 (en) * | 2018-04-27 | 2021-07-29 | Remy Biosciences, Inc. | New Medical Devices, Delivery Vehicles and Manufacturing Thereof |
| KR102893903B1 (ko) * | 2019-02-11 | 2025-12-01 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | Cnp 접합체의 건조 약학 제제 |
| CN116635027A (zh) * | 2020-11-25 | 2023-08-22 | 普罗林科斯有限责任公司 | C-利钠肽的延长释放水凝胶偶联物 |
| EP4337957A1 (en) * | 2021-05-11 | 2024-03-20 | Texas Tech University System | Targeted selenium conjugates as countermeasures for pathogenic viruses and cells |
| AU2022407450A1 (en) * | 2021-12-07 | 2024-07-11 | Biomarin Pharmaceutical Inc. | CNP Therapy |
| JP2025521254A (ja) | 2022-11-02 | 2025-07-08 | ノヴォ ノルディスク アー／エス | Ｃｎｐ化合物 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2561530C (en) | 2004-03-31 | 2014-04-22 | Kazuwa Nakao | Therapeutic or prophylactic agent for arthritis |
| EP3446711A1 (en) * | 2004-03-31 | 2019-02-27 | Kazuwa Nakao | Composition for increasing body height |
| CA2705603A1 (en) | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| EP4029512A1 (en) * | 2009-05-20 | 2022-07-20 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 KR KR1020187019166A patent/KR20180088459A/ko active Pending
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3386531T3 (pl) | 2022-02-28 |
| PT3386531T (pt) | 2021-12-29 |
| RU2018124600A (ru) | 2020-01-13 |
| EP4019038A2 (en) | 2022-06-29 |
| CA3007315A1 (en) | 2017-06-15 |
| MX2018006986A (es) | 2018-09-05 |
| US20220160836A1 (en) | 2022-05-26 |
| EP3386531B1 (en) | 2021-10-13 |
| IL259690B (en) | 2022-10-01 |
| IL259690A (en) | 2018-07-31 |
| RU2021132347A (ru) | 2022-03-24 |
| CN108697766A (zh) | 2018-10-23 |
| WO2017100400A3 (en) | 2017-10-26 |
| DK3386531T3 (da) | 2022-01-03 |
| RU2759679C2 (ru) | 2021-11-16 |
| EP4019038A3 (en) | 2022-09-28 |
| US20190247467A1 (en) | 2019-08-15 |
| EP3386531A2 (en) | 2018-10-17 |
| HRP20211908T1 (hr) | 2022-03-04 |
| JP7104625B2 (ja) | 2022-07-21 |
| RU2018124600A3 (cg-RX-API-DMAC7.html) | 2020-01-13 |
| US12214015B2 (en) | 2025-02-04 |
| AU2024201852A1 (en) | 2024-04-11 |
| HUE057083T2 (hu) | 2022-04-28 |
| KR20180088459A (ko) | 2018-08-03 |
| AU2016365751A1 (en) | 2018-06-21 |
| IL259690B2 (en) | 2023-02-01 |
| US11202819B2 (en) | 2021-12-21 |
| WO2017100400A2 (en) | 2017-06-15 |
| AU2016365751B2 (en) | 2023-12-21 |
| JP2019505486A (ja) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2901769T3 (es) | Uso de variantes de péptidos natriuréticos tipo c para tratar la osteoartritis | |
| ES2608457T3 (es) | Variantes de péptido natriurético de tipo C | |
| AU2008326327A1 (en) | Variants of C-type natriuretic peptide | |
| HK40074902A (en) | Use of c-type natriuretic peptide variants to treat osteoarthritis | |
| RU2850341C2 (ru) | Применение вариантов натрийуретического пептида типа c для лечения остеоартрита | |
| HK1262398B (en) | Use of c-type natriuretic peptide variants to treat osteoarthritis | |
| HK40124042A (en) | Variants of c-type natriuretic peptide | |
| WO2023150693A2 (en) | Neuregulin-4 analogs and methods of using thereof in disease treatment | |
| HK1239519A1 (en) | Variants of c-type natriuretic peptide | |
| HK1239519B (en) | Variants of c-type natriuretic peptide |